Regeneration by regulating the immune system.
Mallia Therapeutics is built on over 20 years of immunological research. Our focus: Translating basic science into new clinically therapies.
From molecule to medicine.
Mallia Therapeutics is the therapeutic division of Mallia, dedicated to exploring the regenerative power of immune modulation. Our active product is MAL-856, a protein structurally related to the soluble sCD83 protein, a key mediator of resoluton of inflammation and tissue regeneration. With a network of academic, industrial and reguatory affair collaborators, we are advancing science into innovative therapies.
Our current research areas.
Hair loss / alopecia.
Targeting hairloss (alopecia) with MAL-856-based therapies.
Wound healing.
Promoting tissue repair and modulation of chronic wounds.
Skin disorders and autoimmune diseases.
Induction of resolution of inflammation by restoring the immune balance.
Why the MAL-856 molecule matters.
The sCD83-based recombinant expressed MAL-856 molecule is at the heart of our therapeutic research. More than two decades of immunological studies have identified sCD83 as a key molecule modulating inflammation and activating regenerative processes. Due to its inflammation resolving mode of action, it represents a completely new and innovative approach to address currently unmet medical needs including different forms of alopecia, wound healing, as well as inflammatory and autoimmune diseases.
Let us advance science together.
Currently, we are collaborating with outstanding scientists performing basic and applied research, physicians and clinicians, research institutions and hospitals. Contact us if you are interested in pushing the boundaries by translating immune insights into therapeutic solutions.
Stay informed.
Whether it concerns the latest research findings, clinical updates, publications or business news – our dedicated Therapeutics News section keeps you well informed.
